Clinical review report: Glycopyrrolate oral solution (Cuvposa) (Medexus Pharmaceuticals, Inc.) : indication: chronic severe drooling, neurologic (pediatric)
The objective of this report is to perform a systematic review of the beneficial and harmful effects of glycopyrrolate oral solution (1 mg/5 mL) indicated to reduce chronic severe drooling in patients three to 18 years of age with neurologic conditions associated with problem drooling
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of glycopyrrolate oral solution (1 mg/5 mL) indicated to reduce chronic severe drooling in patients three to 18 years of age with neurologic conditions associated with problem drooling |
|---|---|
| Physical Description: | 1 PDF file (57 pages) illustrations |